11 citations
,
August 2021 in “Stem Cell Research & Therapy” Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
3 citations
,
September 2020 Dyclonine can effectively reduce skin issues by inhibiting the TRPV3 channel.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Mononuclear cells may protect against certain chemotherapy-induced hair loss.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
October 2025 in “Cell Death and Disease” CD271 is crucial for maintaining healthy skin and preventing inflammation.
July 2025 in “Ultrasound in Medicine & Biology” UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
66 citations
,
February 2013 in “PeerJ” Activating cannabinoid receptor 1 reduces certain keratin levels, potentially aiding psoriasis treatment.
April 2023 in “Journal of Investigative Dermatology” CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.
April 2017 in “Journal of Investigative Dermatology” Removing the Crif1 gene in mouse skin disrupts skin balance and hair growth.
8 citations
,
February 2024 in “Matrix Biology” 4 citations
,
October 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.
6 citations
,
November 2018 in “Case reports in nephrology and dialysis” Rituximab may be an effective treatment for Cronkhite-Canada syndrome with kidney disease.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
64 citations
,
March 2004 in “Journal of Clinical Investigation” Targeting ornithine decarboxylase can help prevent skin cancer.
63 citations
,
May 2011 in “Clinical cancer research” The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
29 citations
,
February 2011 in “PloS one” Astressin-B can reverse and prevent hair loss in stressed mice.
January 2026 in “Therapeutics” SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.
76 citations
,
January 1998 in “Mammalian Genome”
88 citations
,
August 2019 in “Nature communications” Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
57 citations
,
April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology” Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
January 2011 in “Junshi yixue” A mouse model for studying scleroderma in chronic graft-versus-host disease was successfully created.
5 citations
,
June 2022 in “Journal of Oncology” Blocking the Hedgehog pathway may help overcome drug resistance in multiple myeloma.
Dual TCR Treg cells are common in various mouse tissues and show diverse characteristics.
21 citations
,
April 2016 in “International Journal of Oncology” GnRH treatment can reduce breast cancer cell invasion.
3 citations
,
June 2018 in “Internal Medicine” Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
21 citations
,
October 2013 in “Molecular Biology of the Cell” The protein CCN2 controls hair growth by affecting hair follicle formation and stem cell activity in mice.
Ca²⁺-mediated protein citrullination controls cell growth in the CNS and may help treat brain tumors.
5 citations
,
February 2016 in “International Journal of Cancer” Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.